PMID- 31857780
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20200505
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 25
IP  - 46
DP  - 2019 Dec 14
TI  - Two-week bismuth-containing quadruple therapy and concomitant therapy are 
      effective first-line treatments for Helicobacter pylori eradication: A 
      prospective open-label randomized trial.
PG  - 6790-6798
LID - 10.3748/wjg.v25.i46.6790 [doi]
AB  - BACKGROUND: Increasing levels of antibiotic resistance have reduced the 
      Helicobacter pylori (H. pylori) eradication rates afforded by the standard triple 
      therapy. Thus, 2-wk first-line four-drug regimens must be considered. AIM: To 
      analyze the eradication rates of modified bismuth-containing quadruple therapy 
      (mBCQT) and concomitant therapy (CT), the associated adverse events, and 
      compliance. METHODS: Patients infected with H. pylori were prospectively 
      randomized to receive mBCQT or CT for 2 wk. mBCQT featured a proton pump 
      inhibitor (PPI), bismuth, metronidazole, and tetracycline, taken twice daily. CT 
      included a PPI, clarithromycin, metronidazole, and amoxicillin, taken twice 
      daily. The (13)C-urea breath test was performed no earlier than 4 wk after 
      therapy concluded to confirm eradication. If either the histological or rapid 
      urease test was positive, H. pylori infection was diagnosed. RESULTS: The 
      demographic characteristics of 68 patients who received mBCQT and 68 who received 
      CT did not differ significantly. On intention-to-treat analysis, the eradication 
      rate was 88.2% (60/68) in the mBCQT group and 79.4% (54/68) in the CT group (P = 
      0.162). By per-protocol analysis, the respective eradication rates were 98.4% 
      (60/61) and 93.1% (54/58) (P = 0.199). More CT than mBCQT patients experienced 
      adverse events [33.8% (23/68) mBCQT vs 51.5% (35/58) CT patients, respectively, P 
      = 0.037]. All patients showed good compliance [85.3% (58/68) mBCQT vs 82.4% 
      (56/68) CT patients, P = 0.641]. CONCLUSION: The H. pylori eradication rates of 
      the 2-wk mBCQT and CT regimens are high. Most patients show good compliance, and 
      more CT than mBCQT patients experience adverse events.
CI  - (c)The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Kim, So Jeong
AU  - Kim SJ
AD  - College of Medicine, Gachon University Graduate School of Medicine, Incheon 
      21936, South Korea.
FAU - Chung, Jun-Won
AU  - Chung JW
AD  - Division of Gastroenterology, Department of Internal Medicine, Gachon University 
      Gil Medical Center, Incheon 21565, South Korea. junwonchung@hanmail.net.
FAU - Woo, Hyun Sun
AU  - Woo HS
AD  - Division of Gastroenterology, Department of Internal Medicine, Gachon University 
      Gil Medical Center, Incheon 21565, South Korea.
FAU - Kim, Su Young
AU  - Kim SY
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      Wonju College of Medicine, Wonju 26426, South Korea.
FAU - Kim, Jung Ho
AU  - Kim JH
AD  - Division of Gastroenterology, Department of Internal Medicine, Gachon University 
      Gil Medical Center, Incheon 21565, South Korea.
FAU - Kim, Yoon Jae
AU  - Kim YJ
AD  - Division of Gastroenterology, Department of Internal Medicine, Gachon University 
      Gil Medical Center, Incheon 21565, South Korea.
FAU - Kim, Kyoung Oh
AU  - Kim KO
AD  - Division of Gastroenterology, Department of Internal Medicine, Gachon University 
      Gil Medical Center, Incheon 21565, South Korea.
FAU - Kwon, Kwang An
AU  - Kwon KA
AD  - Division of Gastroenterology, Department of Internal Medicine, Gachon University 
      Gil Medical Center, Incheon 21565, South Korea.
FAU - Park, Dong Kyun
AU  - Park DK
AD  - Division of Gastroenterology, Department of Internal Medicine, Gachon University 
      Gil Medical Center, Incheon 21565, South Korea.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Antacids)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 140QMO216E (Metronidazole)
RN  - F8VB5M810T (Tetracycline)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Aged
MH  - Antacids/*therapeutic use
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Bismuth/*therapeutic use
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Metronidazole/therapeutic use
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Tetracycline/therapeutic use
PMC - PMC6920663
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - Bismuth-containing quadruple therapy
OT  - Concomitant therapy
OT  - Therapy
COIS- Conflict-of-interest statement: The authors declare no conflicts of interest.
EDAT- 2019/12/21 06:00
MHDA- 2020/05/06 06:00
PMCR- 2019/12/14
CRDT- 2019/12/21 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2019/12/01 00:00 [revised]
PHST- 2019/12/07 00:00 [accepted]
PHST- 2019/12/21 06:00 [entrez]
PHST- 2019/12/21 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/12/14 00:00 [pmc-release]
AID - 10.3748/wjg.v25.i46.6790 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2019 Dec 14;25(46):6790-6798. doi: 
      10.3748/wjg.v25.i46.6790.